Check-Cap Ltd (NASDAQ:MBAI) Sees Large Decline in Short Interest

Check-Cap Ltd (NASDAQ:MBAIGet Free Report) saw a significant decrease in short interest in the month of August. As of August 14th, there was short interest totaling 26,875 shares, a decrease of 71.9% from the July 30th total of 95,679 shares. Currently, 2.0% of the company’s shares are short sold. Based on an average trading volume of 27,346 shares, the short-interest ratio is presently 1.0 days.

Check-Cap Trading Up 0.2%

NASDAQ MBAI traded up $0.01 during trading hours on Friday, reaching $6.58. The company had a trading volume of 35,021 shares, compared to its average volume of 19,266. The stock has a 50-day moving average of $8.09 and a 200 day moving average of $10.38. Check-Cap has a 1-year low of $4.41 and a 1-year high of $27.44.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Check-Cap in a research note on Tuesday, July 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Get Our Latest Analysis on Check-Cap

About Check-Cap

(Get Free Report)

Check-Cap Ltd. (NASDAQ: MBAI) is an Israel-based medical technology company focused on non-invasive screening solutions for colorectal cancer. The company develops an ingestible imaging capsule and associated detection system intended to provide a patient-friendly alternative to traditional colonoscopy and CT colonography for colorectal screening and polyp detection.

Check-Cap’s technology centers on a swallowable capsule that acquires images of the colon as it traverses the gastrointestinal tract; external detectors capture the transmitted signals and software reconstructs images for clinical review.

Featured Stories

Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with MarketBeat.com's FREE daily email newsletter.